Innate Pharma (IPHA) Other Non-Current Liabilities (2017 - 2025)
Historic Other Non-Current Liabilities for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $520701.4.
- Innate Pharma's Other Non-Current Liabilities rose 6446.41% to $520701.4 in Q2 2025 from the same period last year, while for Jun 2025 it was $520701.4, marking a year-over-year increase of 6446.41%. This contributed to the annual value of $292795.1 for FY2024, which is 5487.07% down from last year.
- According to the latest figures from Q2 2025, Innate Pharma's Other Non-Current Liabilities is $520701.4, which was up 6446.41% from $292795.1 recorded in Q4 2024.
- In the past 5 years, Innate Pharma's Other Non-Current Liabilities ranged from a high of $648791.8 in Q4 2023 and a low of $202009.0 during Q4 2022
- In the last 5 years, Innate Pharma's Other Non-Current Liabilities had a median value of $292795.1 in 2024 and averaged $372265.1.
- Its Other Non-Current Liabilities has fluctuated over the past 5 years, first surged by 22116.98% in 2023, then crashed by 5487.07% in 2024.
- Over the past 5 years, Innate Pharma's Other Non-Current Liabilities (Quarter) stood at $289424.7 in 2021, then plummeted by 30.2% to $202009.0 in 2022, then soared by 221.17% to $648791.8 in 2023, then tumbled by 54.87% to $292795.1 in 2024, then soared by 77.84% to $520701.4 in 2025.
- Its Other Non-Current Liabilities was $520701.4 in Q2 2025, compared to $292795.1 in Q4 2024 and $316605.0 in Q2 2024.